Mindera Health is disrupting the world of medicine. Ashley takes you inside their Carlsbad headquarters to see how this new psoriasis predictive test is changing lives for the better. Mindera Health founder Toby Dickerson explains it all.
See More: Precision Medicine disrupts the medical world | FOX 5 San Diego & KUSI News
Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with Liviniti™, an innovative Pharmacy Benefit Manager, to improve the management of moderate-to-severe psoriasis patients. This pilot program will utilize Mind.Px to improve clinical outcomes while reducing biologic drug costs for self-funded employers.
In the United States, psoriasis affects more than three percent [i] of the population. Moderate-to-severe disease severity accounts for approximately one-third of psoriasis diagnoses.[ii]This auto-immune condition often leads to absenteeism or major problems at work, depression, and other clinical comorbidities.[ii] Specialty drug spending for psoriasis is escalating exponentially, and biologics are often identified by payers, employers, and pharmacy benefit managers as being in their top drug expenditures each year. [iii] Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent[iv], leading to trial-and-error patient treatments and increased healthcare costs.
Mind.Px is a predictive test that uses a patented dermal biomarker patch allowing for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >92 percent positive predictive value.[v] By leveraging precision medicine and matching the patient to the right drug class before treatment begins, clinical outcomes are improved while biologic drug expenditures are optimized.
“We are delighted to partner with a Pharmacy Benefit Manager like Liviniti to introduce precision medicine to psoriasis patients,” says Ron Rocca, CEO of Mindera Health. “We share the core value of introducing innovation to significant markets to decrease drug costs while improving patient outcomes.”
LeAnn C. Boyd, Liviniti CEO adds, “Inflammatory conditions are a major cost trend driver in the specialty pharmacy space. Leveraging pharmacogenomics through our collaboration with Mindera Health supports improved treatment outcomes for patients with psoriasis and reduced plan costs for expensive biologics. Ensuring that patients receive an effective drug early in treatment is a cornerstone of this program, and we are excited to offer Mind.Px to our clients and their members.”
About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.
About Liviniti™
Liviniti is a pioneer in pharmacy benefit innovation. Built by pharmacists, the company offers pass-through pricing within a fully transparent business model that delivers meaningful savings to clients and optimal health outcomes to members. Founded in 2011 as Southern Scripts and rebranded to Liviniti in 2023, the new name reinforces the power of medication to change lives through infinite possibilities. With an approach that delivers savings, clinical value, exceptional service and management of high-cost medications, Liviniti provides pharmacy benefit services to regional and national employers across the US. For more information, visit Liviniti.com.
About Mindera Health
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification.
i Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):10291072. doi:10.1016/j.jaad.2018.11.057.
ii Van Voorhees AS, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide, 7th ed. Table 2-3. https://psoriasis.org/the-pocket-guide.
ii Prime Therapeutics 2012-2015 and 2019-2020 posters titled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”
iv Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.
V Mindera Health. Data on file.
San Diego, CA – November 27th, 2023 – Mindera Health™, a leading provider of precision medicine solutions for psoriasis, today announced that it will be relocating its commercial activities to a new office building at 1221 Liberty Way, Vista, CA 92081 on December 1st, 2023. The new facility is over 19,000 square feet and features a state-of-the-art molecular laboratory.
“As we continue to accelerate our commercial activities, it is necessary to have a state-of-the-art facility that will enable us to expand,” said Ron Rocca, President, and CEO of Mindera Health. “The new building gives us some great collaborative spaces that have already had a positive impact on our projects.”
The new Mindera Health office is designed to foster innovation and collaboration, with open workspaces, meeting rooms, and a dedicated break area. The laboratory is equipped with the latest technology and equipment, allowing Mindera Health to continue to develop and commercialize its innovative precision medicine solutions for psoriasis.
Mindera Health will continue to operate its Kearny Mesa laboratory as licenses and accreditations are transferred to the new location.
“We are excited to move into our new office and laboratory,” said Toby Dickerson, Chief Scientific Officer and Co-Founder. “This is a significant milestone for Mindera Health, and it is a testament to our growth and commitment to providing patients with the best possible care.”
About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
Ron Rocca
Mindera Health
(858) 810-6070
ron.rocca@minderahealth.com
San Diego, CA, Nov. 06, 2023 (GLOBE NEWSWIRE) — Mindera Health today announces the signing a commercial agreement with Occum Health, LLC, a healthcare solutions company that is focused on delivering savings and improved benefits to self-insured employers. Through this agreement, Mindera’s proprietary psoriasis biologic prediction test, Mind.Px, is available to Occum Health’s more than 500 self-insured clients and key strategic partners.
“We are thrilled to have the opportunity to partner with Occum Health in offering Mind.Px to their clients and strategic partners. Mind.Px’s ability to inform biologic class choice in plaque psoriasis patients is a natural fit for Occum Health, who shares in our vision of delivering savings and improved care quality for their clients and their members,” said Ron Rocca, CEO of Mindera Health. “Innovative partnerships of this kind ensure that we are able to raise broad awareness for Mind.Px amongst all healthcare stakeholders and facilitate the adoption of a more personalized approach the treating these patients, that will improve both health and non-health related outcomes.”
“Mind.Px represents an exciting addition to our portfolio.” said Don Marette, President of Occum Health. “New and innovative assets like Mind.Px are key drivers of Occum Health’s continued growth, enhancing the value proposition of our direct-to-employer offerings.”.
In the United States, psoriasis affects more than three percent[i] of the population, leading to healthcare costs of more than $110 billion annually[ii]. Specialty drug spending for psoriasis is escalating at exponential rates, and biologics are often identified by payers, employers and pharmacy benefit managers as being in their top drug expenditures each year[iii]. Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent[iv], leading to trial-and-error patient treatments and increased healthcare costs.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >92 percent positive predictive value[v]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annual cost savings ranging from $5,138 to $13,141 per patient[vi].
______________________
i Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057.
ii Pilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196-203. doi:10.1080/13696998.2018.1557201.
iii Prime Therapeutics 2012-2015 and 2019-2020 posters entitled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”
iv Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.
v Data on file.
vi Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6
San Diego, CA, Oct 23, 2023 (GLOBE NEWSWIRE) — Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, announces that it has signed a provider contract with Contigo Health ConfigureNetTM provider network. This commercial agreement will make Mindera’s psoriasis biologic prediction test, Mind.Px, available to clients and their health plan members served by clients of Contigo Health.
“This significant agreement represents another meaningful milestone in the continued growth and acceptance of tests that enable the most therapeutic and cost-effective decisions,” said Ron Rocca, CEO and President of Mindera Health. “Use of Mind.Px can effectively minimize the trial-and-error approach to psoriasis treatment and provide physicians, patients, and payers with a powerful tool to guide the individual patient to an efficacious drug class based on their transcriptomics — the true vision of precision medicine.”
“We are thrilled to welcome Mindera to the Contigo Health ConfigureNetTM provider network,” said John Strickland, President and CEO of Contigo Health. “The addition of Mindera Health to ConfigureNet™ will offer our client’s health plan members greater access and choice in their dermatologic care.”
In the United States, psoriasis affects more than three percent[i] of the population, leading to healthcare costs of more than $110 billion annually[ii]. Specialty drug spending for psoriasis is escalating at exponential rates, and biologics are often identified by payers, employers and pharmacy benefit managers as being in their top drug expenditures each year[iii]. Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent[iv], leading to trial-and-error patient treatments and increased healthcare costs.
About Contigo Health, LLC:
Contigo Health, LLC, a consolidated subsidiary of Premier, Inc., is leading the way to financially sustainable healthcare. Contigo Health is a health benefits platform that leads direct-to-employer and direct-to-provider relationships. It is relentlessly focused on revolutionizing healthcare through appropriate, cost-effective, transparent, and thoughtful benefits design. Contigo Health® products includes ConfigureNet™, a robust network offering nationwide provider access, Sync Health Plan TPA, Payvider Activation, and Centers of Excellence 360. To learn more, please visit www.contigohealth.com, and follow us on LinkedIn, YouTube, and X.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >92 percent positive predictive value[v]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annual cost savings ranging from $5,138 to $13,141 per patient[vi].
______________________
i Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057.
ii Pilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196-203. doi:10.1080/13696998.2018.1557201.
iii Prime Therapeutics 2012-2015 and 2019-2020 posters entitled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”
iv Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.
v Data on file.
vi Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6
Contact:
Ron Rocca, CEO
Mindera Health
mindpx@minderahealth.com
858.810.6070
Mindera Health, a precision medicine company developing personalized tools to optimize patient outcomes, today announced that additional patent protection has been issued in Australia for the core technology behind the dermal biomarker patch.
Australian patent number 2020239750 was issued August 3, 2023 and covers devices that can extract dermal biomarkers in situ. The inventors discovered that a patch with covalently modified microprojections can efficiently capture and extract meaningful quantities of biomarkers from the skin. This patent adds to existing patent protection for the dermal biomarker patch technology in the United States, Europe, Australia, China, Hong Kong, and Korea. The term of the patent extends until December 2033. This brings the total number of issued or allowed patents related to the Company’s dermal biomarker patch technology to 12.
“We are pleased to have been issued additional patent coverage in Australia for the Dermal Biomarker Patch,” said Tobin Dickerson, Mindera Health’s Chief Scientific Officer and Co-Founder. “This technology underpins tests such as Mind.Px™, a test designed to optimize psoriasis biologic treatment decisions and reduce trial and error treatment paradigms.”
About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
San Diego, CA, Oct. 10, 2023 (GLOBE NEWSWIRE) — Mindera Health today announced that the General Services Administration (GSA) has granted a 5 year contract award to Mindera Health enabling access to their proprietary technology, Mind.Px. The Mind.Px test is the first and only test that provides a personalized approach selecting the class of biologic therapy a patient with plaque psoriasis is most likely to respond to. The decision is effective today and enables access to Mind.Px for those eligible for treatment at government-affiliated facilities including the over 9.6 million veterans, active duty, retirees and their families that are served by the Veteran’s Administration Health System and Department of Defense Medical Treatment Facilities, and others.
“Mind.Px addresses an unmet need in the effective management of plaque psoriasis patients by informing the selection of the most efficacious class of biologic therapy for a particular patient.” said Dr. Jeffrey Travers, Professor and Chair of Pharmacology and Toxicology and Professor of Dermatology at the Boonshoft School of Medicine at Wright State University and VA investigator at the Dayton VA Medical Center with no formal ties to Mindera Health. “This agreement will not only serve the patients that seek care in the VA and DOD Facilities, but will also afford the Dermatology Residents-in-training the opportunity to learn to manage psoriasis patients while leveraging this advance in personalized medicine.”
“We applaud the GSA/VA’s commitment to enabling access to new and innovative technologies like Mind.Px and are honored to participate in improving the care for psoriasis, while at the same time eliminating waste and improving cost-outcomes, within the largest integrated health network in the world,” said Ron Rocca CEO of Mindera Health.
About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
You can learn more about Mind.Px at www.minderahealth.com or by emailing Mindera at mindpx@minderahealth.com.
San Diego, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) — Mindera Health™ today announces the signing of a network provider contract with MediNcrease Health Plans, a national provider network and provider advocacy firm. This commercial agreement will make Mindera’s psoriasis biologic prediction test, Mind.Px™, available to the more than 15 million lives served by Clients and Payers of MediNcrease.
“Our vision is to enable plaque psoriasis patients and their physicians to optimize therapeutic decisions by using the Mind.Px test’s dermal biomarker patch to extract biomarkers from the skin. The extraordinary cost of biologic treatment and the failure rate of initiating the wrong therapy can be overcome with our precision test. This aligns with MediNcrease’s goals of providing payers improved savings and service to their members,” said Mindera Health CEO Ron Rocca.
In the United States, psoriasis affects more than three percent of the population[i], leading to healthcare costs of more than $110 billion annually.[ii] Specialty drug spending for psoriasis is escalating at exponential rates, and biologics are often identified by payers, employers and pharmacy benefit managers as being in their top drug expenditures each year.[iii] Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent[iv], leading to trial-and-error patient treatments and increased healthcare costs.
“We are thrilled to welcome Mindera Health to the MediNcrease provider network,” said Linda Plaster, Chief Executive Officer of MediNcrease Health Plans. “This exciting relationship affirms continued commitment to our specialty lab services network expansion and increasing the accessibility of specialized diagnostic testing solutions.”
About MediNcrease Health Plans
MediNcrease is a uniquely positioned national provider network and provider advocacy firm servicing the commercial health, workers’ compensation, and auto medical markets. Its advanced provider network and negotiation solutions not only help facilitate millions of dollars in expedited payments to providers each year, but also provide medical payers with dramatically improved savings and service over traditional PPO networks. The result is a 100 percent defensible and transparent solution for both providers and payers. For more information, visit the company’s website at https://medincrease.com.
About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
[i] Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057.
[ii] Pilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196-203. doi:10.1080/13696998.2018.1557201.
[iii] Prime Therapeutics 2012-2015 and 2019-2020 posters entitled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”
[iv] Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.
Ron Rocca to Become Chief Executive Officer
SAN DIEGO, CA – May 11, 2023 – Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive leadership team. The company has announced industry veteran Ron Rocca will succeed George Mahaffey as President and Chief Executive Officer. Mr. Rocca will also serve as a Director of the company. Mr. Mahaffey, who joined the company in 2020, helped lead the company’s transition from the R&D stage through the commercial launch of Mindera Health’s first test.
“On behalf of the board, I want to thank George for his valuable contributions to Mindera Health,” said Joe Cook, III, Chairman of Mindera Health and Co-Founder and Managing Director of Mountain Group Partners. “We are grateful for all that he has helped us accomplish since taking the helm and wish him the best in his future endeavors.”
“It has been my pleasure to work with such a talented team of professionals over the past three years and to assist in bringing the Mind.Px precision medicine test to market. I wish the company all the best as they expand usage of this important and innovative technology,” said Mr. Mahaffey.
“I am extremely excited to join the Mindera Health team. With a total addressable market of over $2 billion in the U.S. alone, Mind.Px has the opportunity to enable huge improvements in patient care while reducing the overall healthcare spend on this disease. In addition to psoriasis, Mindera Health’s proprietary platform also provides access to rich biomarkers that will enable us to develop precision medicine tests for a wide range of diseases,” said Mr. Rocca.
Mr. Cook went on to say, “We are very excited to have Ron join Mindera Health as we ramp up our commercial efforts with Mind.Px and advance a number of additional tests in our pipeline. Ron’s demonstrated commitment to help physicians improve patient care while driving commercial adoption and reimbursement aligns well with the mission of Mindera Health.”
Mr. Rocca brings over two decades of biotech and diagnostics industry experience, including eleven years of developing and commercializing diagnostic products for autoimmune-related diseases. His prior role was President and CEO of Exagen Inc. (NASDAQ: XGN) which commercialized a suite of testing products enabling healthcare providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Prior to Exagen, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostic company focused on diseases in gastroenterology and oncology. He helped grow the company’s sales to $200 million-plus annually before playing an instrumental role in the $1.4 billion acquisition by Nestlé Health Science S.A. in 2011. Prior to Prometheus, Mr. Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company.
Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University. Mr. Rocca will assume his new role at Mindera Health immediately.
About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
About Mountain Group Partners
Founded in 2002, Mountain Group Partners is a Nashville-based venture capital firm that invests in early-stage companies in the life sciences and disruptive technology sectors. The firm brings over 100 years of combined operational experience and has invested in more than 60 companies. www.mtngp.com
###
Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending
Project will evaluate Mind.Px’s™ impact on physician “trial and error” prescribing behavior and overall net savings by prescribing the correct biologic class the first time
SAN DIEGO, CA – April 11, 2023 – Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, has initiated a coverage with evidence project with Highmark Inc. and its health plan affiliates for Pennsylvania, West Virginia and Delaware. The program will evaluate trends in physician utilization, patient outcomes, drug switching, and overall net savings versus a control group.
In the United States, psoriasis affects more than three percent[i] of the population, leading to healthcare costs of more than $110 billion annually.ii Specialty drug spending for psoriasis is escalating at exponential rates, and biologics are often identified by payers, employers and pharmacy benefit managers as being in their top drug expenditures each year.[ii]I Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percentiv, leading to trial-and-error patient treatments and increased healthcare costs.
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >92 percent positive predictive valuev. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annual cost savings ranging from $5,138 to $13,141 per patientvi.
“Use of Mind.Px can effectively minimize the trial-and-error approach to psoriasis treatment and provide physicians, patients, and payers with a powerful tool to guide the individual patient to an efficacious drug class based on their transcriptomics — the true vision of precision medicine,” commented George Mahaffey, President and CEO of Mindera Health. “We look forward to working with Highmark to accelerate the emergence of new technologies, like Mind.Px, to advance psoriasis patient care while reducing unnecessary spending.”
About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.
About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.
I Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057.
ii Pilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196-203. doi:10.1080/13696998.2018.1557201.
iii Source: Prime Therapeutics 2012-2015 and 2019-2020 posters entitled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”
iv Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.
v Mindera Health. Data on file.
vi Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6
© Copyright 2024, Mindera Health I ISO 13485:2016 CERTIFIED PRIVACY POLICY I TERMS OF USE..
